CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.36BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9910xvs all stocks
52-Week Change
13.25%vs all stocks
Market Capitalization
1.36BUSDvs all stocks (USD)
Enterprise Value
1.11BUSDvs all stocks (USD)
Forward P/E
-7.97xvs Biotechnology peers
Price to Book (MRQ)
3.58xvs Biotechnology peers
Enterprise to EBITDA
-7.13xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-25.97%vs Biotechnology peers
Return on Equity (TTM)
-39.80%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-155.00MUSDvs all stocks (USD)
Net Income (TTM)
-140.35MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-111.64MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-68.83MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-143.00MUSDvs all stocks (USD)
Pre-tax Income
-129.47MUSDFY2025 · Dec 31, 2025Net Income
-129.47MUSDFY2025 · Dec 31, 2025EBIT
-143.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-141.78MUSDFY2025 · Dec 31, 2025Research & Development
109.82MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
33.19MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-129.47MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-103.21MUSDFY2025 · Dec 31, 2025Free Cash Flow
-103.92MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
46.16MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-129.47MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.22MUSDFY2025 · Dec 31, 2025Stock-based Compensation
25.04MUSDFY2025 · Dec 31, 2025Capital Expenditures
-712.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-399.82MUSDFY2025 · Dec 31, 2025Sale of Investments
252.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-148.03MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.40MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
241.97MUSDFY2025 · Dec 31, 2025Shares Outstanding
103.64MSharesUpdated Sep 28, 2026Float Shares
88.69MSharesUpdated Sep 28, 2026Shares Short
17.53MSharesUpdated Sep 28, 2026Short Ratio
15.02daysvs all stocks
Short % of Shares Outstanding
17.09%vs all stocks
% Held by Insiders
1.59%vs all stocks
% Held by Institutions
123.10%vs all stocks
Total Cash (MRQ)
264.76MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.55USDUpdated Sep 28, 2026Total Debt (MRQ)
6.00MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0157xvs Biotechnology peers
Current Ratio (MRQ)
13.19xvs Biotechnology peers
Book Value per Share (MRQ)
3.68USDUpdated Sep 28, 2026Total Assets
408.89MUSDvs all stocks (USD)
Total Current Assets
288.47MUSDFY2025 · Dec 31, 2025Total Liabilities
24.53MUSDFY2025 · Dec 31, 2025Total Non-current Assets
120.42MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.11MUSDFY2025 · Dec 31, 2025Total Current Liabilities
20.42MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
45.67MUSDFY2025 · Dec 31, 2025Other Short-term Investments
235.82MUSDFY2025 · Dec 31, 2025Accounts Payable
3.82MUSDFY2025 · Dec 31, 2025Short-term Debt
3.33MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
4.11MUSDFY2025 · Dec 31, 2025Common Stock (Book)
11.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-692.24MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
384.36MUSDvs all stocks (USD)
52-Week Low
7.23USDUpdated Sep 28, 202652-Week High
14.93USDUpdated Sep 28, 202652-Week Change
13.25%vs all stocks
Beta
0.9910xvs all stocks
50-Day MA
12.69USDUpdated Sep 28, 2026200-Day MA
10.74USDUpdated Sep 28, 2026Avg 10-Day Volume
1.77MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.31MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.30USDUpdated Sep 28, 2026Other Income / Expense
13.54MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.76
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Market cap is $1.36B, above the global median of $1.18BNotable
Market cap (USD): 1,364,068,952Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Genrix Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Xinhua Pharmaceutical Company Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Garden Bio-chemical High-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule